Pilot Study of 89-Zr Panitumumab in Pancreas Cancer

Not Recruiting

Trial ID: NCT04833959


The main purpose of the study is to assess the safety of 89Zr-panitumumab as a molecular imaging agent in patients with (metastatic) pancreas cancer.

Official Title

Pilot Study of 89Zr Panitumumab in Pancreas Cancer

Stanford Investigator(s)

Andrei Iagaru
Andrei Iagaru

Professor of Radiology (Nuclear Medicine)

George A. Poultsides, MD, MS
George A. Poultsides, MD, MS

Professor of Surgery (General Surgery) at the Stanford University Medical Center

George A. Fisher Jr.
George A. Fisher Jr.

Colleen Haas Chair in the School of Medicine


Inclusion Criteria:

   - Confirmed diagnosis of pancreatic cancer.

Exclusion Criteria:

   - Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive
   heart failure (CHF); significant liver disease; or unstable angina within 6 months
   prior to enrollment.

   - History of infusion reactions to monoclonal antibody therapies.

   - Pregnant or breastfeeding.

   - Subjects receiving Class IA (quinidine, procainamide) or Class III (dofetilide,
   amiodarone, sotalol) antiarrhythmic agents.

   - Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis.

   - Severe renal disease or anuria.

   - Known hypersensitivity to deferoxamine or any of its components.


drug: 89Zr-panitumumab

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Alexander A Valencia

New Trial Alerts